Evidence map›Paper›PMID 33607966›Full record

Observational studyBMC cancer2021

Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).

Karin Ribi, Beat Thürlimann, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum and 5 more

Open access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

Karin RibiInternational Breast Cancer Study Group (IBCSG), Bern, Switzerland. karin.ribi@ibcsg.org.ORCID http://orcid.org/0000-0003-4724-1197
Beat ThürlimannKantonsspital St. Gallen, St. Gallen, Switzerland.
Corinne SchärSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
Daniel DietrichSwiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
Richard CathomasKantonsspital Graubünden, Chur, Switzerland.
Ursina Zürrer-HärdiKantonsspital Winterthur, Winterthur, Switzerland.
Thomas von BrielKlinik Hirslanden, Zürich, Switzerland.
Sandro AnchisiHôpital du Valais, Sion, Switzerland.
Pierre BohanesCentre de Chimiothérapie Anti-Cancéreuse, Lausanne, Switzerland.
Veronika BlumKantonsspital Luzern, Luzern, Switzerland.
Philippe von BurgBurgerspital Solothurn, Solothurn, Switzerland.
Meinrad MannhartAndreasklinik Cham Zug, Cham, Switzerland.
Clemens B CasparKantonsspital Baden, Baden, Switzerland.
Roger von Moos *Kantonsspital Graubünden, Chur, Switzerland.
Michael Mark *Kantonsspital Graubünden, Chur, Switzerland.
Kantonsspital Graubünden · CHSwiss Group For Clinical Cancer Research · CHHirslanden Andreasklinik Cham Zug · CHHôpital du Valais · CHInternational Breast Cancer Study Group · CHKantonsspital Baden · CHKantonsspital St. Gallen · CHKantonsspital Winterthur · CHKlinik Hirslanden · CHLuzerner Kantonsspital · CHSolothurner Spitäler · CH

Funding

Amgen Not applicableSwiss Cancer League (SCL) Not applicableSwiss Cancer Research Foundation (SCS) Not applicableSwiss State Secretary for Education, Research and Innovation (SERI) Not applicable
6 · The paper itself

Abstract

backgroundBone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited.

methodsThis real world, cross-sectional study enrolled patients over a 3-month period through oncologists across Switzerland. Patients were ≥ 18 years, had solid tumors and at least one bone metastasis, and received routine care for bone metastases. Physicians provided data on BTA-related practices, risk of bone complications and BTA regimen. Patients completed questionnaires about pain (BPI-SF), general and bone pain-related QoL (FACT-G, FACT-BP) and treatment satisfaction (FACIT-TS-G).

resultsEighteen sites recruited 417 patients. Based on the FACT-BP, 42% of the patients indicated not having bone pain. According to the BPI-SF, 28% reported no, 43% mild, 14% moderate, and 15% severe pain, respectively. Patients not treated with a BTA had better overall QoL (FACT-G: p = 0.031) and bone pain-related QoL (FACT-BP, p = 0.007) than those treated with a BTA. All pain and other QoL scales did not differ between groups. Patients perceived at 'low risk of bone complications' by their physician not receiving a BTA reported less pain and better QoL than those considered at 'low risk' but receiving BTA treatment or those considered at 'high risk' regardless of BTA treatment. Overall satisfaction with the treatment was good; almost 50% of patients reporting that they were completely satisfied.

conclusionsOverall, pain and QoL did not differ according to BTA treatment or physicians' risk perception. Patient with low risks not receiving BTA treatment reported least pain and highest QoL scores. These results may suggest that treating physicians assess bone complication risk appropriately and treat patients accordingly, but they need to be confirmed by objective determination of longitudinal skeletal complication risk.

Indexed as

AdultAgedAged, 80 and overBone Density Conservation AgentsBone NeoplasmsCancer PainCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeoplasmsQuality of LifeSurveys and QuestionnairesSwitzerlandBone Density Conservation AgentsBone metastasesBone-pain related quality of lifeBone-targeting agentsNon-interventionalPatient-reported painPatterns of care

Identifiers

PMID33607966
PMCPMC7893880
OpenAlexW3132470280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.